DESCRIPTION (provided by applicant): We have shown that activating protein translation can drive tumorigenesis in mouse models. For example, the eIF4E translation factor can cause tumor development in mice alone or with c-Myc. However, it is unclear exactly how increased translation can promote tumor development. We speculate that the activation of translation directly increases the production of specific anti-apoptotic and oncogenic activities. We will test this hypothesis in our proposal using a mosaic mouse lymphoma model and advanced polyribosome profiling techniques. We previously used a mouse lymphoma model to show the oncogenic effect of translational activation. In Aim 1 we will use the same mouse model to generate lymphomas in vivo that are driven by translational activation or arise through a translation-independent mechanism. To identify exactly which mRNAs are preferentially translated, we will then use polyribosome fractionation and deep sequencing of ribosome-associated mRNAs. Next, we will test the tumor relevant functions of individual candidate genes in vitro and in our mouse model. Notably, we have identified the anti-apoptotic Mcl1 as a first translationally controlled oncoprotein, and have characterized its function. These experiments will now serve as a template for the study of additional candidates (see preliminary studies and Aim 2). In Aim 3 we will use our preclinical lymphoma model to test the therapeutic benefit of blocking Mcl1 with small molecule (obatoclax). Mcl1 is highly expressed in some human lymphomas, where it corresponds to markers of translational activation. We speculate that tumors driven by translational activation may show an increased requirement for Mcl1. This preclinical trial is in collaboration with the Lymphoma Service at Memorial Hospital, and will directly feed into their clinical trial on the same compound. Together, this is an innovative study into the biology and clinical relevance of translational regulation in tumorigenesis and therapy. All the necessary tools are in place, e.g. the mosaic mouse model, polyribosome fractionation and 454 sequencing techniques, and our preclinical trial has the potential for near term clinical application. Moreover, our recent publications in Genes & Development indicate a track record of successful studies that have provided new insights in this understudied area of tumor biology. |